## **Patent Application** Attorney Docket No. PC 10303AJTJ

Examiner: J. Spear 68 Group Art Unit: 161

hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 9th day of July 2003.

ture of person mailing) Patricia Botelho

(Typed or printed name of person)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Elizabeth King, et al.

**APPLICATION NO.: 09/425,622** 

FILING DATE: October 22, 1999

TITLE: Controlled-Release Pharmaceutical

**Formulations** 

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

Sir.

## Amendment Under Rule 114

The above-identified application was allowed on April 11, 2003. Payment of the Issue Fee is accordingly due on or before July 11, 2003. In lieu of paying the Issue Fee, Applicants are submitting this amendment and the accompanying Request For Continued Examination in order to claim additional preferred embodiments to which Applicants are entitled.

Please amend the application as follows by adding new claims 54-66 (previously allowed claims 31-53 are shown for completeness):

In the claims:

Claims 1-30 (canceled)

31. (allowed) A sustained-release formulation for oral administration containing a cGMP PDE-5 inhibitor, wherein the cGMP PDE-5 inhibitor is present in a core which is coated with a release rate-controlling membrane, provided that 4/97, M4, (1/7)